Techbase Medical Defense (ATD)
Abstract
Project TM3 supports preclinical and early phase clinical development of vaccines, therapeutic drugs, and diagnostic capabilities to provide safe and effective medical defense against validated biological threat agents or emerging infectious disease biothreats including bacteria, toxins, and viruses. A portion of Project NT3, Techbase Non-Traditional Agents Defense, will merge into this Project starting in FY21. Individual efforts in this project include: - Evaluating innovative biotechnology approaches to advance medical systems designed to rapidly identify, diagnose, prevent, and treat disease due to exposure to biological threat agents. - In addition this project supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes, skin decontaminants and therapeutic drugs against identified and emerging chemical warfare threat agents. Entry of candidate vaccines, therapeutics, and diagnostic technologies into advanced development is facilitated by the development of technical data packages that support the Food and Drug Administration (FDA) Investigational New Drug (IND) processes, DoD acquisition regulations, and the oversight of early phase clinical trials in accordance with FDA guidelines. - Non-Traditional Agent (NTA) Defense includes chemical diagnostics, medical pretreatments, therapeutics, detection, and protection and hazard mitigation. FY20-22 reorganizes, renames legacy Bullet titles and introduces new Bullets (Thrust Areas). These new "Thrust" titles are in line with the CBDP Core Capability Areas and intended to provide more detail and traceability from the S&T program to advanced development.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2022
- Source ID
- TM3_0603384BP_3_0400_PB_2022
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (ATD)
- Child Accomplishment: 1) CARES Act - A Highly Multiplexed Point-of-Care Digital Protein Assay Platform with Digital Molecular Capability
- Child Accomplishment: 2) CARES Act - Host Response (Organs-on-chips)
- Child Accomplishment: 3) CARES Act - SARS COV-2 VSV vaccine
- Child Accomplishment: 4) Internal COVID - New Horizons Diagnostics Corporation - Serology
- Child Accomplishment: 5) Internal COVID - Serology Development and IV&V Testing
- Child Accomplishment: 6) Internal COVID - Systems Approach to Medical Countermeasures Development
- Child Accomplishment: 7) Internal COVID - Systems Approach to Medical Countermeasures Development
- Child Accomplishment: 8) Internal COVID - VSV SARS CoV-2 vaccine
- Child Accomplishment: 9) Medical Diagnostics
- Child Accomplishment: 10) Battlefield Readiness
- Child Accomplishment: 11) Battlefield Readiness
- Child Accomplishment: 12) Chemical Diagnostics
- Child Accomplishment: 13) Chemical Diagnostics
- Child Accomplishment: 14) Clinical Evaluation
- Child Accomplishment: 15) Emerging Threats
- Child Accomplishment: 16) Diagnostic Building Blocks
- Child Accomplishment: 17) Vaccine Platforms and Research Tools
- Child Accomplishment: 18) Viral Vaccines
- Child Accomplishment: 19) Bacterial/Toxin Vaccines
- Child Accomplishment: 20) Bacterial, Viral and Toxin Prophylaxis
- Child Accomplishment: 21) Chemical Therapeutics
- Child Accomplishment: 22) Nerve Agent Prophylaxis/Pretreatments
- Child Accomplishment: 23) Pharmaceutical Based Agents (PBAs)
- Child Accomplishment: 24) Reactivators of AChE as Therapeutics (ReACT)
- Child Accomplishment: 25) Bacterial Therapeutics
- Child Accomplishment: 26) Viral Therapeutics
- Child Accomplishment: 27) Toxin Therapeutics
- Child Accomplishment: 28) Medical Countermeasures Initiative
- Child Accomplishment: 29) Laboratory Operations & Support